An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)

Trial Profile

An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Acronyms GLADIATOR
  • Sponsors CoLucid Pharmaceuticals; Eli Lilly
  • Most Recent Events

    • 19 Sep 2016 An interim results published in the CoLucid Pharmaceuticals Media Release.
    • 19 Sep 2016 According to a CoLucid Pharmaceuticals media release, till date 1,155 patients (approximately 45%) has been randomized in this trial
    • 19 Sep 2016 An interim update from GLADIATOR was presented at a symposium during the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016), according to a CoLucid Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top